Your session is about to expire
← Back to Search
Oral Azacitidine for Leukemia
Study Summary
This trial is testing azacitidine to see if it can help patients with T-cell large granular lymphocytic leukemia that has returned or did not respond to previous treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 216 Patients • NCT01566695Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My hemoglobin is below 10 g/dL and I feel very tired.I have been diagnosed with a specific type of leukemia (T-LGLL or NK LGL) based on my blood cell counts and genetic tests.I need regular blood transfusions for my anemia.I agree to use effective birth control during the study.I have tried at least one treatment for my condition and stopped it more than 14 days ago or 5 half-lives ago, whichever is longer.I need treatment for T-LGL leukemia.I have another cancer, but it's related to my T-LGLL condition.I am 18 years old or older.I have previously used 5-azacytidine or decitabine.I do not have an active infection needing treatment, nor HIV or hepatitis B/C.I am on a low dose of steroids for an autoimmune condition or to treat T-LGL symptoms.I can take care of myself and perform daily activities.I have low white blood cell counts and get infections often.
- Group 1: Treatment (Oral Azacitidne)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What maladies can best be addressed with Oral Azacitidine?
"Oral Azacitidine is a frequently used intervention for treating malignant neoplasms, having at least 20-30% blast cells in the blood and neutropenia or thrombocytopenia."
Is the research team currently recruiting participants?
"Per the information posted by clinicaltrials.gov, this research project is presently seeking volunteers for participation. It was first published on May 1st 2022 and has been modified most recently on April 18th 2022."
What is the maximum number of participants being accepted for this research?
"Affirmative. According to information hosted on the clinicaltrials.gov website, this trial was initially publicized on May 1st 2022 and updated lastly on April 18th 2022. The study is recruiting 21 patients at a single medical centre for participation."
What precedent studies have been conducted regarding Oral Azacitidine?
"Currently, 173 trials are investigating the potential of Oral Azacitidine to treat various ailments. Of these ongoing studies, 32 have entered Phase 3 testing. While a majority of these clinical studies for this medication take place in Saint Louis, Missouri, there are 5664 other locations hosting related experiments."
Share this study with friends
Copy Link
Messenger